Grifols (NASDAQ:GRFS) Raised to Strong-Buy at Berenberg Bank

Berenberg Bank upgraded shares of Grifols (NASDAQ:GRFS) to a strong-buy rating in a report released on Tuesday, Zacks.com reports.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $8.69 on Tuesday. The firm has a market cap of $5.97 billion, a P/E ratio of 8.60 and a beta of 0.50. The company has a quick ratio of 0.80, a current ratio of 1.68 and a debt-to-equity ratio of 1.06. The company has a 50 day moving average of $8.82 and a 200 day moving average of $7.77. Grifols has a twelve month low of $5.30 and a twelve month high of $12.15.

Grifols (NASDAQ:GRFS) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The company had revenue of $1.96 billion during the quarter. As a group, research analysts expect that Grifols will post 0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its holdings in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 1,135 shares during the period. NBC Securities Inc. raised its stake in shares of Grifols by 2.8% during the third quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 1,433 shares during the period. Signaturefd LLC boosted its holdings in Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares during the last quarter. US Bancorp DE increased its holdings in Grifols by 12.3% in the third quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 2,256 shares during the last quarter. Finally, Creative Planning grew its position in shares of Grifols by 26.4% during the 3rd quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock valued at $154,000 after buying an additional 3,614 shares during the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.